Auflistung SFB-relevante Publikationen B2:

[TERT-Promoter Mutational Status in Glioblastoma - Is There an Association With Amino Acid Uptake on Dynamic 18F-FET PET?](#)
Unterrainer M, Ruf V, von Rohr K, Suchorska B, Mittlmeier LM, Beyer L, Brendel M, Wenter V, Kunz WG, Bartenstein P, Herms J, Niyazi M, Tonn JC, **Albert NL.**
Front Oncol. 2021 Apr 27;11:645316.

[Use of PET Imaging in Neuro-Oncological Surgery.](#)
Holzgreve A, **Albert NL**, Galldiks N, Suchorska B.
Cancers (Basel). 2021 Apr 26;13(9):2093.

[PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging.](#)
Holzgreve A, Biczok A, Ruf VC, Liesche-Starnecker F, Steiger K, Kirchner MA, Unterrainer M, Mittlmeier L, Herms J, Schlegel J, Bartenstein P, Tonn JC, **Albert NL**, Suchorska B.
Front Oncol. 2021 Mar 30;11:646387.

[Dual PET Imaging of an H3K27M-Mutant Glioma With 18F-GE-180 and 18F-FET PET.](#)
Vettermann FJ, Unterrainer M, Ruf V, Fleischmann DF, Rupprecht R, Forbrig R, Herms J, Tonn JC, Belka C, Bartenstein P, Niyazi M, **Albert NL.**
Clin Nucl Med. 2020 Dec;45(12):992-993.

[TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study.](#)
Unterrainer M, Fleischmann DF, Vettermann F, Ruf V, Kaiser L, Nelwan D, Lindner S, Brendel M, Wenter V, Stöcklein S, Herms J, Milenkovic VM, Rupprecht R, Tonn JC, Belka C, Bartenstein P, Niyazi M, **Albert NL.**Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1368-1380.

[Comment on "Hypometabolic gliomas on FET-PET-is there an inverted U-curve for survival?"](#)
Galldiks N, Verger A, Zaragori T, Unterrainer M, Suchorska B, Lohmann P, Tonn JC, Langen KJ, **Albert NL.**
Neuro Oncol. 2019 Dec 17;21(12):1612-1613.

[Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic ^{18}F-FET PET.](#)
Vettermann F, Suchorska B, Unterrainer M, Nelwan D, Forbrig R, Ruf V, Wenter V, Kreth FW, Herms J, Bartenstein P, Tonn JC, **Albert NL.**
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2581-2589.

[Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients.](#)
Galldiks N, Unterrainer M, Judov N, Stoffels G, Rapp M, Lohmann P, Vettermann F, Dunkl V, Suchorska B, Tonn JC, Kreth FW, Fink GR, Bartenstein P, Langen KJ, **Albert NL.**
Neuro Oncol. 2019 Oct 9;21(10):1331-1338.

[Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning.](#)
Suchorska B, Schüller U, Biczok A, Lenski M, **Albert NL**, Giese A, Kreth FW, Ertl-Wagner B, Tonn JC, Ingrisch M.
Eur J Cancer. 2019 Jan;107:15-27.

[Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET.](#)
Vettermann FJ, Felsberg J, Reifenberger G, Hasselblatt M, Forbrig R, Berding G, la Fougère C, Galldiks N, Schittenhelm J, Weis J, **Albert NL**, Schüller U.
Clin Nucl Med. 2018 Dec;43(12):895-898.

[Voxel-wise analysis of dynamic ^{18}F-FET PET: a novel approach for non-invasive glioma characterisation.](#)
Vomacka L, Unterrainer M, Holzgreve A, Mille E, Gosewisch A, Brosch J, Ziegler S, Suchorska B, Kreth FW, Tonn JC, Bartenstein P, **Albert NL**, Böning G.
EJNMMI Res. 2018 Sep 10;8(1):91.

[^{18}F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy.](#)
Suchorska B, Unterrainer M, Biczok A, Sosnova M, Forbrig R, Bartenstein P, Tonn JC, **Albert NL***, Kreth FW*.
J Neurooncol. 2018 Sep;139(3):721-730.

[Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas.](#)
Kunz M, **Albert NL**, Unterrainer M, la Fougere C, Egensperger R, Schüller U, Lutz J, Kreth S, Tonn JC, Kreth FW, Thon N.
Neuro Oncol. 2019 Feb 14;21(2):274-284.

[Detection of Cerebrospinal Fluid Dissemination of Recurrent Glioblastoma Using TSPO-PET With 18F-GE-180.](#)
Unterrainer M, Fleischmann DF, Lindner S, Brendel M, Rupprecht R, Tonn JC, Belka C, Bartenstein P, Niyazi M, **Albert NL.**
Clin Nucl Med. 2018 Jul;43(7):518-519.

The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?
Unterrainer M, Niyazi M, Ruf V, Bartenstein P, **Albert NL.**
Neuro Oncol. 2017 Nov 29;19(12):1698-1699.

Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma.
Suchorska B, Giese A, Biczok A, Unterrainer M, Weller M, Drexler M, Bartenstein P, Schüller U, Tonn JC, **Albert NL.**
Neuro Oncol. 2018 Jan 22;20(2):279-288.

TSPO PET for glioma imaging using the novel ligand ^{18}F-GE-180: first results in patients with glioblastoma.
Albert NL, Unterrainer M, Fleischmann DF, Lindner S, Vettermann F, Brunegraf A, Vomacka L, Brendel M, Wenter V, Wetzel C, Rupprecht R, Tonn JC, Belka C, Bartenstein P, Niyazi M.
Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2230-2238.

Projekt B2: SFB relevante Publikationen der aktuellen Förderperiode

Volmar MNM, Cheng J, Alenezi H, Richter S, Haug A, Hassan Z, Goldberg M, Li Y, Hou M, Herold-Mende C, Maire CL, Lamszus K, Flüh C, Held-Feindt J, Gargiulo G, Topping GJ, Schilling F, Saur D, Schneider G, Synowitz M, Schick JA, Kälin RE, **Glass R**. Cannabidiol converts NFκB into a tumor suppressor in glioblastoma with defined antioxidative properties.

Neuro Oncol. **2021**: noab095. doi: 10.1093/neuonc/noab095.

Kälin RE, Cai L, Li Y, Zhao D, Zhang H, Cheng J, Zhang W, Wu Y, Eisenhut K, Janssen P, Schmitt L, Enard W, Michels F, Flüh C, Hou M, Kirchleitner SV, Siller S, Schiemann M, Andrä I, Montanez E, Giachino C, Taylor V, Synowitz M, Tonn JC, von Baumgarten L, Schulz C, Hellmann I, **Glass R.** TAMEP are brain tumor parenchymal cells controlling neoplastic angiogenesis and progression. **Cell Syst. 2021;** 12(3): 248-262.e7. doi: 10.1016/j.cels.2021.01.002.

Schmitt MJ, Company C, Dramaretska Y, Barozzi I, Göhrig A, Kertalli S, Großmann M, Naumann H, Sanchez-Bailon MP, Hulsman D, **Glass R,** Squatrito M, Serresi M, Gargiulo G. Phenotypic Mapping of Pathologic Cross-Talk between Glioblastoma and Innate Immune Cells by Synthetic Genetic Tracing. **Cancer Discov. 2021**; 11(3): 754-777. doi: 10.1158/2159-8290.CD-20-0219.

Cai L, Kirchleitner SV, Zhao D, Li M, Tonn JC, **Glass R,** Kälin RE. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells. **Int J Mol Sci. 2020;** 21(2): 612. doi: 10.3390/ijms21020612.

Yang Y, Dodbele S, Park T, **Glass R**, Bhat K, Sulman EP, Zhang Y, Abounader R. J. MicroRNA-29a inhibits glioblastoma stem cells and tumor growth by regulating the PDGF pathway. **Neurooncol. 2019**;145(1):23-34. doi: 10.1007/s11060-019-03275-z.

Mallm JP, Windisch P, Biran A, Gal Z, Schumacher S, **Glass R,** Herold-Mende C, Meshorer E, Barbus M, Rippe K. Glioblastoma initiating cells are sensitive to histone demethylase inhibition due to epigenetic deregulation**. Int J Cancer. 2020**; 146(5): 1281-1292. doi: 10.1002/ijc.32649.

Mastrella G, Hou M, Li M, Stöcklein V, Zdouc N, Volmar MNM, Miletic H, Reinhard S, Herold-Mende C, Kleber S, Eisenhut K, Gargiulo G, Synowitz M, Vescovi AL, Harter PN, Penninger JM, Wagner E, Mittelbronn M, Bjerkvig R, Hambardzumyan D, Schüller U, Tonn JC, Radke J, **Glass R** and Kälin RE. APLN/APLNR-targeting improves anti- angiogenic efficiency and blunts pro-invasive side effects of VEGFA/VEGFR2-blockade in glioblastoma. **Cancer Res., 2019**; 79(9): 2298-2313.

Mughal AA, Zhang L, Fayzullin A, Server A, Li Y, Wu Y, **Glass R,** Meling T, Langmoen IA, Leergaard TB, Vik-Mo EO. Patterns of Invasive Growth in Malignant Gliomas-The Hippocampus Emerges as an Invasion-Spared Brain Region. **Neoplasia, 2018**;20(7):643-656.

Neumann JE, Wefers AK, Lambo S, Bianchi E, Bockstaller M, Dorostkar MM, Meister V, Schindler P, Korshunov A, von Hoff K, Nowak J, Warmuth-Metz M, Schneider MR, Renner- Müller I, Merk DJ, Shakarami M, Sharma T, Chavez L, **Glass R,** Chan JA,

Taketo MM, Neumann P, Kool M, Schüller U. A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors. **Nat Med., 2017**; 23(10):1191-1202.

Audia A, Conroy S, **Glass R,** Bhat KPL. The Impact of the Tumor Microenvironment on the Properties of Glioma Stem-Like Cells. **Front Oncol., 2017;** 7:143.

Kontakt:

Prof. Dr. rer. nat. Rainer Glaß
Leiter der Neurochirurgischen Forschung am Klinikum der Universität München
Rainer.Glass@med.uni-muenchen.de https://www.gsn.uni-muenchen.de/people/faculty/associate/glass/index.html

Dr. sc. nat. Roland Kälin
Gruppenleiter Neurovaskuläre Forschung Roland.Kaelin@med.uni-muenchen.de